(RELX) Relx - Ratings and Ratios
Analytics, Databases, Legal Research, Trade Shows, Risk Models
Dividends
| Dividend Yield | 1.59% |
| Yield on Cost 5y | 3.55% |
| Yield CAGR 5y | 5.28% |
| Payout Consistency | 90.3% |
| Payout Ratio | 79.0% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 20.5% |
| Value at Risk 5%th | 34.5% |
| Relative Tail Risk | 2.09% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.93 |
| Alpha | -27.04 |
| CAGR/Max DD | 0.45 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.435 |
| Beta | 0.480 |
| Beta Downside | 0.348 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.69% |
| Mean DD | 5.52% |
| Median DD | 2.96% |
Description: RELX Relx December 02, 2025
RELX PLC (NYSE: RELX) delivers data-driven analytics and decision-support tools to professional and business customers across North America, Europe and the rest of the world through four operating segments: Risk, Scientific-Technical-Medical (STM), Legal, and Exhibitions. The Risk segment blends public and proprietary data with AI-enabled models to help clients assess credit, fraud and operational risk. The STM segment supplies curated scientific literature, clinical trial data and research platforms that accelerate discovery and improve health outcomes. The Legal segment offers regulatory, case law and business intelligence that streamlines counsel workflows and boosts productivity. The Exhibitions segment combines in-person events with digital engagement tools to facilitate market insight, sourcing and transaction activity. The company, originally Reed Elsevier, rebranded to RELX in 2015 and traces its roots to 1903, with headquarters in London.
Key recent metrics: 2023 revenue reached £9.0 billion, with the Risk segment contributing ~38% of total sales and showing a 6% YoY growth driven by heightened demand for cyber-risk analytics. The STM segment’s subscription-based platform Elsevier ScienceDirect recorded a 9% increase in active institutional users, reflecting continued investment in research infrastructure. A macro driver for RELX is the global shift toward data-centric compliance and ESG reporting, which is expanding the addressable market for its risk-and-legal intelligence services.
For a deeper dive into RELX’s valuation dynamics and scenario analysis, explore the detailed breakdown on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 3.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.35 > 0.02 and ΔFCF/TA 9.14 > 1.0 |
| NWC/Revenue: -16.14% < 20% (prev -39.34%; Δ 23.20% < -1%) |
| CFO/TA 0.37 > 3% & CFO 5.31b > Net Income 3.82b |
| Net Debt (7.32b) to EBITDA (5.89b): 1.24 < 3 |
| Current Ratio: 0.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.84b) vs 12m ago -3.46% < -2% |
| Gross Margin: 64.67% > 18% (prev 0.61%; Δ 6406 % > 0.5%) |
| Asset Turnover: 146.4% > 50% (prev 114.4%; Δ 32.01% > 0%) |
| Interest Coverage Ratio: 6.21 > 6 (EBITDA TTM 5.89b / Interest Expense TTM 671.0m) |
Altman Z'' 1.41
| A: -0.21 (Total Current Assets 2.73b - Total Current Liabilities 5.77b) / Total Assets 14.32b |
| B: 0.13 (Retained Earnings 1.89b / Total Assets 14.32b) |
| C: 0.32 (EBIT TTM 4.16b / Avg Total Assets 12.87b) |
| D: 0.18 (Book Value of Equity 2.22b / Total Liabilities 12.13b) |
| Altman-Z'' Score: 1.41 = BB |
Beneish M -3.17
| DSRI: 0.75 (Receivables 2.16b/1.99b, Revenue 18.84b/13.05b) |
| GMI: 0.94 (GM 64.67% / 61.09%) |
| AQI: 0.83 (AQ_t 0.80 / AQ_t-1 0.97) |
| SGI: 1.44 (Revenue 18.84b / 13.05b) |
| TATA: -0.10 (NI 3.82b - CFO 5.31b) / TA 14.32b) |
| Beneish M-Score: -3.17 = AA |
ValueRay F-Score (Strict, 0-100) 87.63
| 1. Piotroski: 8.0pt |
| 2. FCF Yield: 7.91% |
| 3. FCF Margin: 26.69% |
| 4. Debt/Equity: 3.46 |
| 5. Debt/Ebitda: 1.24 |
| 6. ROIC - WACC: 25.22% |
| 7. RoE: 123.8% |
| 8. Revenue Trend: 94.77% |
| 9. EPS Trend: 38.20% |
What is the price of RELX shares?
Over the past week, the price has changed by -0.97%, over one month by -2.94%, over three months by -14.45% and over the past year by -17.48%.
Is RELX a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RELX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54 | 35.2% |
| Analysts Target Price | 54 | 35.2% |
| ValueRay Target Price | 43.5 | 8.9% |
RELX Fundamental Data Overview January 21, 2026
P/E Trailing = 30.1667
P/E Forward = 21.9298
P/S = 7.9264
P/B = 25.9121
P/EG = 2.067
Revenue TTM = 18.84b GBP
EBIT TTM = 4.16b GBP
EBITDA TTM = 5.89b GBP
Long Term Debt = 5.53b GBP (from longTermDebt, last quarter)
Short Term Debt = 1.94b GBP (from shortTermDebt, last quarter)
Debt = 7.54b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.32b GBP (from netDebt column, last quarter)
Enterprise Value = 63.58b GBP (56.25b + Debt 7.54b - CCE 211.0m)
Interest Coverage Ratio = 6.21 (Ebit TTM 4.16b / Interest Expense TTM 671.0m)
EV/FCF = 12.65x (Enterprise Value 63.58b / FCF TTM 5.03b)
FCF Yield = 7.91% (FCF TTM 5.03b / Enterprise Value 63.58b)
FCF Margin = 26.69% (FCF TTM 5.03b / Revenue TTM 18.84b)
Net Margin = 20.26% (Net Income TTM 3.82b / Revenue TTM 18.84b)
Gross Margin = 64.67% ((Revenue TTM 18.84b - Cost of Revenue TTM 6.66b) / Revenue TTM)
Gross Margin QoQ = 66.25% (prev 64.72%)
Tobins Q-Ratio = 4.44 (Enterprise Value 63.58b / Total Assets 14.32b)
Interest Expense / Debt = 2.91% (Interest Expense 219.0m / Debt 7.54b)
Taxrate = 23.69% (304.0m / 1.28b)
NOPAT = 3.18b (EBIT 4.16b * (1 - 23.69%))
Current Ratio = 0.47 (Total Current Assets 2.73b / Total Current Liabilities 5.77b)
Debt / Equity = 3.46 (Debt 7.54b / totalStockholderEquity, last quarter 2.18b)
Debt / EBITDA = 1.24 (Net Debt 7.32b / EBITDA 5.89b)
Debt / FCF = 1.46 (Net Debt 7.32b / FCF TTM 5.03b)
Total Stockholder Equity = 3.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 29.66% (Net Income 3.82b / Total Assets 14.32b)
RoE = 123.8% (Net Income TTM 3.82b / Total Stockholder Equity 3.08b)
RoCE = 48.35% (EBIT 4.16b / Capital Employed (Equity 3.08b + L.T.Debt 5.53b))
RoIC = 32.25% (NOPAT 3.18b / Invested Capital 9.85b)
WACC = 7.03% (E(56.25b)/V(63.79b) * Re(7.68%) + D(7.54b)/V(63.79b) * Rd(2.91%) * (1-Tc(0.24)))
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.39%
[DCF Debug] Terminal Value 84.47% ; FCFF base≈4.20b ; Y1≈5.18b ; Y5≈8.83b
Fair Price DCF = 97.93 (EV 185.09b - Net Debt 7.32b = Equity 177.77b / Shares 1.82b; r=7.03% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.20 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.77 | Revenue CAGR: 12.89% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.91 | Chg30d=+0.014 | Revisions Net=+1 | Growth EPS=+10.2% | Growth Revenue=+6.6%
Additional Sources for RELX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle